Reshma Ramachandran
MD, MPP, MHS
Assistant Professor of Medicine (General Medicine)
Research & Publications
Biography
News
Locations
Coauthors
Selected Publications
- HPR82 Assessment of Supporting Evidence and Postmarketing Requirements for Therapeutic Indications With Real-Time Oncology Drug Review, 2018-2023Mooghali M, Mohammad A, Wallach J, Mitchell A, Ross J, Ramachandran R. HPR82 Assessment of Supporting Evidence and Postmarketing Requirements for Therapeutic Indications With Real-Time Oncology Drug Review, 2018-2023. Value In Health 2024, 27: s208. DOI: 10.1016/j.jval.2024.03.1151.
- HPR109 Evaluation of Evidence Informing Medicare’s Coverage With Evidence Development Decision UpdatesMooghali M, Moneer O, Janda G, Dhruva S, Ross J, Ramachandran R. HPR109 Evaluation of Evidence Informing Medicare’s Coverage With Evidence Development Decision Updates. Value In Health 2024, 27: s214. DOI: 10.1016/j.jval.2024.03.1178.
- Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease TreatmentsWallach J, Yoon S, Doernberg H, Glick L, Ciani O, Taylor R, Mooghali M, Ramachandran R, Ross J. Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments. JAMA 2024, 331: 1646-1654. PMID: 38648042, PMCID: PMC11036312, DOI: 10.1001/jama.2024.4175.
- Funding of evidence included within public comments submitted to inform Medicare national coverage determinationsLu A, Ji R, Magee M, Ross J, Ramachandran R, Redberg R, Dhruva S. Funding of evidence included within public comments submitted to inform Medicare national coverage determinations. Health Affairs Scholar 2024, 2: qxae064. PMID: 38919964, PMCID: PMC11196998, DOI: 10.1093/haschl/qxae064.
- Implications for Public Health Regulation if Chevron Deference Is OverturnedAgrawal S, Ross J, Ramachandran R. Implications for Public Health Regulation if Chevron Deference Is Overturned. JAMA 2024, 331: 1443-1444. PMID: 38506706, DOI: 10.1001/jama.2024.3654.
- Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication ApprovalsMooghali M, Mohammad A, Wallach J, Mitchell A, Ross J, Ramachandran R. Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals. JAMA Network Open 2024, 7: e249233. PMID: 38691363, PMCID: PMC11063797, DOI: 10.1001/jamanetworkopen.2024.9233.
- Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional studyMooghali M, Mitchell A, Skydel J, Ross J, Wallach J, Ramachandran R. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study. BMJ Medicine 2024, 3: e000802. PMID: 38596814, PMCID: PMC11002412, DOI: 10.1136/bmjmed-2023-000802.
- Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications.Nagel K, Ramachandran R, Lipska K. Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications. Diabetes Care 2024 PMID: 38536964, DOI: 10.2337/dci23-0042.
- Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016–2019 dataQureshi O, Ramachandran R, Ross J. Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016–2019 data. Journal Of Pharmaceutical Policy And Practice 2024, 17: 2312374. PMID: 38434725, PMCID: PMC10906125, DOI: 10.1080/20523211.2024.2312374.
- US FDA breakthrough therapy designation and consumer drug advertising: a recipe for confusionPatel N, Mohammad A, Ross J, Ramachandran R. US FDA breakthrough therapy designation and consumer drug advertising: a recipe for confusion. The BMJ 2024, 384: e076138. PMID: 38383007, DOI: 10.1136/bmj-2023-076138.
- Pivotal Trial Demographic Representation and Clinical Development Times for Oncology TherapeuticsWong A, Miller J, Mooghali M, Ramachandran R, Ross J, Wallach J. Pivotal Trial Demographic Representation and Clinical Development Times for Oncology Therapeutics. JAMA 2023, 330: 2392-2394. PMID: 38079163, PMCID: PMC10714278, DOI: 10.1001/jama.2023.21958.
- Association of health benefits and harms of Christmas dessert ingredients in recipes from The Great British Bake Off: umbrella review of umbrella reviews of meta-analyses of observational studiesWallach J, Gautam A, Ramachandran R, Ross J. Association of health benefits and harms of Christmas dessert ingredients in recipes from The Great British Bake Off: umbrella review of umbrella reviews of meta-analyses of observational studies. The BMJ 2023, 383: e077166. PMID: 38123175, DOI: 10.1136/bmj-2023-077166.
- Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus TherapiesSkydel J, Ramachandran R, Suttiratana S, Ross J, Burns C, Wallach J. Geographic and Demographic Representation in Industry-Sponsored, US-Based Clinical Trials of Systemic Lupus Erythematosus Therapies. The Journal Of Rheumatology 2023, 51: jrheum.2023-0920. PMID: 38101910, PMCID: PMC10922605, DOI: 10.3899/jrheum.2023-0920.
- Ensuring Public Trust in an Empowered FDARoss J, Berg K, Ramachandran R. Ensuring Public Trust in an Empowered FDA. New England Journal Of Medicine 2023, 388: 1249-1251. PMID: 37017494, DOI: 10.1056/nejmp2300438.
- If Left Unchecked: Lessons Learned from Unfettered U.S. Government Support of the NIH-Moderna VaccineRamachandran R. If Left Unchecked: Lessons Learned from Unfettered U.S. Government Support of the NIH-Moderna Vaccine. The Journal Of Law, Medicine & Ethics 2023, 51: 41-45. PMID: 38433676, PMCID: PMC10911987, DOI: 10.1017/jme.2023.155.